Display options
Cite
van Luijn MM, Chamuleau ME, Ossenkoppele GJ, et al. Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation. Oncoimmunology. 2012;1(2):211-213doi: 10.4161/onci.1.2.18100.
van Luijn, M. M., Chamuleau, M. E., Ossenkoppele, G. J., van de Loosdrecht, A. A., & Marieke van Ham, S. (2012). Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation. Oncoimmunology, 1(2), 211-213. https://doi.org/10.4161/onci.1.2.18100
van Luijn, Marvin M, et al. "Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation." Oncoimmunology vol. 1,2 (2012): 211-213. doi: https://doi.org/10.4161/onci.1.2.18100
van Luijn MM, Chamuleau ME, Ossenkoppele GJ, van de Loosdrecht AA, Marieke van Ham S. Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation. Oncoimmunology. 2012 Mar 01;1(2):211-213. doi: 10.4161/onci.1.2.18100. PMID: 22720245; PMCID: PMC3376995.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2012 Mar 01;1(2):211-213. doi: 10.4161/onci.1.2.18100.

Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation.

Oncoimmunology

Marvin M van Luijn, Martine E D Chamuleau, Gert J Ossenkoppele, Arjan A van de Loosdrecht, S Marieke van Ham

Affiliations

  1. Department of Hematology; Cancer Center Amsterdam; VU Institute for Cancer and Immunology; VU University Medical Center; Amsterdam, The Netherlands ; Department of Immunopathology; Sanquin Research and Landsteiner Laboratory; Academic Medical Center; University of Amsterdam; Amsterdam, The Netherlands.

PMID: 22720245 PMCID: PMC3376995 DOI: 10.4161/onci.1.2.18100

Abstract

In this overview, we discuss the role of class II-associated invariant chain peptide (CLIP) in acute myeloid leukemia (AML), one of the few tumors expressing HLA class II. The clinical impact, function and regulation of CLIP expression on leukemic cells is addressed, indicating its potential as immunotherapeutic target in AML.

References

  1. EMBO J. 2008 Jan 9;27(1):1-5 - PubMed
  2. Nat Rev Immunol. 2005 Apr;5(4):296-306 - PubMed
  3. Cancer Res. 2008 Dec 1;68(23):9601-7 - PubMed
  4. Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6886-91 - PubMed
  5. Cancer Immunol Immunother. 2010 Dec;59(12):1825-38 - PubMed
  6. Am J Pathol. 2011 Nov;179(5):2157-61 - PubMed
  7. N Engl J Med. 2011 Aug 25;365(8):754-7 - PubMed
  8. Cancer Res. 2004 Aug 15;64(16):5546-50 - PubMed
  9. Cancer Res. 2011 Apr 1;71(7):2507-17 - PubMed
  10. Cancer Immunol Immunother. 2011 Jan;60(1):37-47 - PubMed

Publication Types